U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H20O6P2S3
Molecular Weight 466.469
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TEMEFOS

SMILES

COP(=S)(OC)OC1=CC=C(SC2=CC=C(OP(=S)(OC)OC)C=C2)C=C1

InChI

InChIKey=WWJZWCUNLNYYAU-UHFFFAOYSA-N
InChI=1S/C16H20O6P2S3/c1-17-23(25,18-2)21-13-5-9-15(10-6-13)27-16-11-7-14(8-12-16)22-24(26,19-3)20-4/h5-12H,1-4H3

HIDE SMILES / InChI

Description

Temefos (Diphos, Temephos) is an organophosphate larvicide, used to treat water infested with disease-carrying insects including mosquitoes, midges, and black fly larvae. Temefos affects the central nervous system through inhibition of cholinesterase, results in death before reaching the adult stage. Diphos has been used in trials studying the treatment of Plasmodium Falciparum Malaria. Temephos was first registered in the United States in 1965 by American Cyanamid Company for a number of uses including citrus fruits, pet collars, and mosquito control. A Registration Standard was issued in August, 1981. In response to EPA's 1991 Data Call-In, American Cyanamid dropped all uses except the mosquito larvicide use in non-potable waters and requested a low volume minor use waiver for relief from the data requirements associated with that use.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
Humans ingested 256 mg/kg of Temefos for five days and 64 mg/kg for four months without any symptoms or detectable effects on blood enzyme activity.
Route of Administration: Oral
In Vitro Use Guide
Regarding the cytostatic effect in human lymphocytes, temephos (10 uM) caused a significant decrease in the percentage of binucleated cells and in the nuclear division index as well as an increase in the apoptotic cell frequency, which was not the case for HepG2 cells.